 |
|
Brain Monoamine Oxidase A Binding in Major Depressive DisorderRelationship to Selective Serotonin Reuptake Inhibitor Treatment, Recovery, and Recurrence
Jeffrey H. Meyer, MD, PhD;
Alan A. Wilson, PhD;
Sandra Sagrati, BSc;
Laura Miler, BSc;
Pablo Rusjan, PhD;
Peter M. Bloomfield, MSc;
Michael Clark, BSc;
Julia Sacher, MD, PhD;
Aristotle N. Voineskos, MD;
Sylvain Houle, MD, PhD
Arch Gen Psychiatry. 2009;66(12):1304-1312.
Context Highly significant elevations in regional brain monoamine oxidase A (MAO-A) binding were recently reported during major depressive episodes (MDEs) of major depressive disorder (MDD). The relationship between MAO-A levels and selective serotonin reuptake inhibitor (SSRI) treatment, recovery, and recurrence in MDD is unknown.
Objectives To determine whether brain MAO-A binding changes after SSRI treatment, whether brain MAO-A binding normalizes in subjects with MDD in recovery, and whether there is a relationship between prefrontal and anterior cingulate cortex MAO-A binding in recovery and subsequent recurrence of MDE.
Design Case-control study.
Setting Tertiary care psychiatric hospital.
Participants Twenty-eight healthy subjects, 16 subjects with an MDE secondary to MDD, and 18 subjects with MDD in recovery underwent carbon 11–labeled harmine positron emission tomography scans. Subjects with MDE were scanned before and after 6 weeks of SSRI treatment. All were otherwise healthy, nonsmoking, and medication free. Subjects with MDD in recovery were followed up for 6 months after MAO-A binding measurement.
Main Outcome Measure Monoamine oxidase A VT, an index of MAO-A density, was measured in the prefrontal cortex, anterior cingulate cortex, posterior cingulate cortex, dorsal putamen, ventral striatum, thalamus, anterior temporal cortex, midbrain, and hippocampus.
Results Monoamine oxidase A VT was significantly elevated in each brain region both during MDE and after SSRI treatment as compared with healthy controls. During recovery, MAO-A VT was significantly elevated in each brain region; however, those who went on to recurrence had significantly higher MAO-A VT in the prefrontal and anterior cingulate cortex than those who did not.
Conclusions Elevated MAO-A binding after SSRI treatment indicates persistence of a monoamine-lowering process not present in health. This provides a strong conceptual rationale for continuing SSRI treatment during early remission. Greater MAO-A binding in the prefrontal and anterior cingulate cortex in subjects with MDD in recovery and its association with subsequent recurrence argue that deficient monoamine neuromodulation may persist into recovery and contribute to recurrence.
Author Affiliations: Vivian M. Rakoff PET Imaging Centre (Drs Meyer, Wilson, Rusjan, Sacher, Voineskos, and Houle, Messrs Bloomfield and Clark, and Mss Sagrati and Miler) and Mood and Anxiety Disorders Division (Dr Meyer), Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
This Month in Archives of General Psychiatry
Arch Gen Psychiatry. 2009;66(12):1285.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Monoamine Oxidase A Binding in the Prefrontal and Anterior Cingulate Cortices During Acute Withdrawal From Heavy Cigarette Smoking
Bacher et al.
Arch Gen Psychiatry 2011;68:817-826.
ABSTRACT
| FULL TEXT
Serotonin Receptor Imaging: Clinically Useful?
Parsey
JNM 2010;51:1495-1498.
ABSTRACT
| FULL TEXT
Elevated Brain Monoamine Oxidase A Binding in the Early Postpartum Period
Sacher et al.
Arch Gen Psychiatry 2010;67:468-474.
ABSTRACT
| FULL TEXT
|
